13 resultaten
TECHNICAL FIELD
This invention pertains to polyamine compounds, including polyamine/guanidine and polyamine/biguanide compounds, useful for treatment of cancer and/or parasitic infections, and for inhibition of lysine-specific demethylase.
BACKGROUND
Polyamines are found in both eukaryotic and
CROSS REFERENCE TO RELATED APPLICATION(S)
This application is a 35 U.S.C. .sctn.371 National Phase Entry Application from PCT/BR2007/000175, filed Jul. 6, 2007, and designating the United States. This application also claims the benefit of Brazilian Application No. PI-0602640-0, filed Jul. 6, 2006,
BACKGROUND OF THE INVENTION
Platinum complexes, the prototype of cisplatin, have been widely used as active anticancer agents (Ardizzoni et al., 1999; Nitiss, 2002) in a variety of human tumors, including testicular, ovarian, bladder carcinoma, head and neck, and non-small cell lung cancers. The
BACKGROUND OF THE INVENTION
Platinum complexes, the prototype of cisplatin, have been widely used as active anticancer agents (Ardizzoni et al., 1999; Nitiss, 2002) in a variety of human tumors, including testicular, ovarian, bladder carcinoma, head and neck, and non-small cell lung cancers. The
BACKGROUND OF THE INVENTION
Most nucleated eukaryotic cells, whether unicellular organisms or constituents of multicellular organism including humans, contain acidified vacuoles that are critical for cellular maintenance and function. In mammalian cells, these vacuoles comprise lysosomes and other
BACKGROUND
Parasitic diseases affect millions of people worldwide with severe social and economic consequences. The protozoan parasites Leishmania major, and Trypanosoma cruzi, cause leishmaniasis and Chagas' disease (CD) respectively. There are several clinical forms of leishmaniasis: visceral
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage filing under 35 U.S.C. .sctn. 371 of International Patent Application No. PCT/CN2013/077796, filed on Jun. 24, 2013, entitled "Use of Ivermectin and Derivatives Thereof", which claims the benefit of and priority to Chinese
FIELD OF THE INVENTION
The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of
FIELD OF THE INVENTION
This invention relates to the baculovirus envelope glycoprotein called the gp64 envelope fusion protein (gp64 EFP), also known as gp64 or gp67 (hereafter "gp67"). The present inventors have suprisingly discovered that this glycoprotein induces both Type I (alpha, beta) and
The present invention is related to certain novel peptides and to the use of such peptides and to compositions containing such peptides. More particularly, the present invention is directed to pharmaceutical uses and compositions of such peptides.
In accordance with an aspect of the present
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to thymidylate synthase (TS) inhibitors. In particular, this invention relates to certain tosylproline analogs that are TS inhibitors, to methods of making them, to pharmaceutical compositions containing them, and to their
CROSS-REFERENCE TO RELATED APPLICATIONS
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
None
BACKGROUND OF THE INVENTION
The invention relates to the treatment of viral, bacterial, parasitic, benign and malignant proliferative diseases, neurodegenerative diseases, inflammatory
The present invention relates to a new use, in particular a new pharmaceutical use, for cyclosporins, as well as to new cyclosporins as novel compounds per se.
The cyclosporins comprise a class of structurally distinctive, cyclic, poly-N-methylated undecapeptides, generally possessing